Multiple myeloma · 22 regimens
Cost vs Efficacy · 9 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
KTD Variant #01 | — | R 206 076 | 28d | — | — | ~4 | ~R 461 336 indirect | — |
Thalidomide and Dexamethasone (TD) Variant #06 | — | R 64 543 | 30d | ~18.6 mo | ~63.2 mo | ~18 | ~R 678 160 PFS proxy · indirect | 3 |
Thalidomide and Prednisolone (TP) Variant #01 | — | R 29 231 | 28d | — | — | ~14 | ~R 213 215 PFS proxy · indirect | 1 |
VTD Variant #01 | — | R 14 059 | 21d | ~35.8 mo | — | ~4 | ~R 54 155 PFS proxy · indirect | 1 |
RVD Variant #07 | — | R 10 329 | 21d | 46.2 mo | — | 8 | R 77 075 PFS proxy | 3 |
Bortezomib and Melphalan Variant #01 | — | R 7 262 | — | — | — | ~1 | ~R 7 262 indirect | — |
VMP Variant #01 | — | R 6 897 | 42d | ~17.3 mo | ~56.4 mo | ~6 | ~R 41 381 PFS proxy · indirect | 8 |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | 33.6 mo | — | 8 | R 54 096 PFS proxy | 3 |
Melphalan monotherapy, then Melphalan and Busulfan Variant #01 | — | R 6 051 | — | — | — | ~1 | ~R 6 051 indirect | — |
Melphalan and Methylprednisolone Variant #01 | — | R 3 244 | — | — | 54.1 mo | 1 | R 3 244 PFS proxy | — |
MPR Variant #01 | — | R 2 245 | 28d | 22.4 mo | — | 9 | R 20 209 PFS proxy | 2 |
Lenalidomide and Prednisone (RP) Variant #02 | — | R 2 182 | 28d | ~37.5 mo | — | ~5 | ~R 10 910 PFS proxy · indirect | 1 |
DCEP Variant #03 | — | R 2 157 | 28d | — | — | ~1 | ~R 2 157 indirect | — |
MEL200, then MEL220 and Dexamethasone Variant #01 | — | R 1 050 | — | — | — | ~1 | ~R 1 050 indirect | — |
Melphalan monotherapy, then Melphalan and TBI Variant #02 | — | R 850 | — | — | — | ~1 | ~R 850 indirect | — |
Melphalan monotherapy, then Busulfan and Fludarabine, then allo HSCT Variant #01 Partial | — | R 500 | — | — | — | ~1 | ~R 500 indirect | — |
Melphalan monotherapy, then TBI, then allo HSCT Variant #01 Partial | — | R 500 | — | — | — | ~1 | ~R 500 indirect | — |
Melphalan monotherapy Variant #01 | — | R 73 | 42d | 50.0 mo | — | 18 | R 1 320 PFS proxy | 4 |
Tandem melphalan Variant #03 | — | — | — | 43.2 mo | — | 1 | — | 4 |
Melphalan and TBI Variant #01 | — | — | — | — | — | ~1 | — | — |
TP Partial | — | — | — | — | — | — | — | — |
No consolidation Partial | — | — | — | — | — | — | — | — |
22 of 22 regimens shown